Keyphrases
National Cohort Study
100%
Glucose-lowering Drugs
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Confidence Interval
77%
Odds Ratio
77%
Kidney Disease
33%
Hypoglycemia
22%
Heart Failure
22%
Medicare Advantage
22%
Insurance
22%
Black Men
22%
Myocardial Infarction
11%
Diabetes
11%
Health Outcomes
11%
Evidence-based
11%
Cardiovascular Disease
11%
Diabetes Management
11%
Diabetes Complications
11%
Low Risk
11%
Type 2 Diabetic Patients
11%
Cardioprotection
11%
Adverse Effects
11%
Retrospective Analysis
11%
Cardiorenal
11%
Data Warehouse
11%
Clinical Factors
11%
Commercially Insured
11%
Severe Hypoglycemia
11%
Hypoglycemia Risk
11%
Prior Myocardial Infarction
11%
Chronic Diabetes
11%
Risk-benefit
11%
Protective Benefits
11%
Commercial Insurance
11%
Multivariable Logistic Regression
11%
Diabetes Type 2
11%
Pharmacy Claims Data
11%
Diabetes Type 1
11%
Medical Claims Data
11%
Renal Protection
11%
Appropriateness of Use
11%
Glucose Effect
11%
Risk Paradox
11%
Clinical Comorbidities
11%
Treatment Risk
11%
Medicine and Dentistry
Cohort Analysis
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Odds Ratio
77%
Hypoglycemia
44%
Nephropathy
33%
Medicare
22%
Diabetes
22%
Myocardial Infarction
22%
Congestive Heart Failure
22%
Cardiovascular System
11%
Insulin Dependent Diabetes Mellitus
11%
Maturity Onset Diabetes of the Young
11%
Complications of Diabetes Mellitus
11%
Health Outcomes
11%
Patient with Type 2 Diabetes
11%
Adverse Event
11%
Logistic Regression Analysis
11%
Comorbidity
11%